Program Project in Models of Breast Cancer

乳腺癌模型项目

• 批准号: 8741842
• 负责人: LARRY NORTON
• 金额: $ 262.91万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-01 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8741842
• 关键词: Address; Biological; Breast Cancer Model; Budgets; Cessation of life; Clinical; Critiques; Development; Doctor of Medicine; Doctor of Philosophy; ERBB2 gene; Feedback; Funding; Genetic; Genetically Engineered Mouse; Goals; Growth; IL8RB gene; In Situ; Institution; Knowledge; Laboratory Animal Models; Lead; Leadership; Lesion; Lung; Maintenance; Malignant Neoplasms; Mammary Tumorigenesis; Mediating; Mediator of activation protein; Molecular; Mus; Neoplasm Metastasis; PIK3CG gene; Pathway interactions; Principal Investigator; Proteins; Proto-Oncogene Proteins c-akt; RNA Interference; Reagent; Recommendation; Regulation; Research Personnel; Role; Signal Pathway; Signal Transduction; Site; Testing; Therapeutic; Vertebrates; anticancer research; base; epithelial to mesenchymal transition; gene function; helix-loop-helix protein differentiation inhibitor; human TGFB1 protein; human subject protection; improved; in vivo; inhibitor/antagonist; innovation; malignant breast neoplasm; mouse model; prognostic; programs; promoter; prospective; public health relevance; response; therapeutic development; tool; treatment strategy; tumorigenesis; twist protein

DESCRIPTION (provided by applicant): Proposed is a continuation of a productive, integrated, innovative Program Project in animal and laboratory models of breast cancer with actual and prospective clinical translatability. The goal is to address fundamental biological questions to advance our knowledge of metastasis and aberrant growth regulation and thereby improve all aspects of breast cancer prognostication, prediction of therapeutic benefit, and treatment. It is comprised of four projects, each led by a leader in the field, an Administrative Core to provide oversight and management, and a highly innovative RNAi Core to provide critical reagents as well as genetically engineered mouse models. Avoidance of duplication of effort, intellectual and material synergy, and orientation toward real clinical needs are hallmarks of this effort. The Projects and their Principal Investigators are: (1) TGF-beta, PI3K and HER2 pathways in breast cancer metastasis (Joan Massague, Ph.D.), (2) Role and regulation of Id1 during breast cancer metastasis initiation (Robert Benezra, Ph.D.), (3) Development of mechanism-based strategies for the treatment of advanced breast cancer with PI3K pathway inhibitors (Neal Rosen, Ph.D. and Sarat Chandarlapaty, M.D.)' and (4) RND1 - Mediated breast cancer suppression (Filippo G. Giancotti, M.D., Ph.D.). Administrative Core A is to be led by Larry Norton, M.D., who is also the Principal investigator of the Program. The Core B in RNAi Tools for Breast Cancer Research is to be led by Scott Lowe, Ph.D.

描述（由申请人提供）：拟议是具有实际和前瞻性临床可翻译性的乳腺癌动物和实验室模型的生产性，综合性，创新性项目的延续。目标是解决基本的生物学问题，以提高我们对转移和异常生长调节的认识，从而改善乳腺癌预后、治疗益处预测和治疗的各个方面。它由四个项目组成，每个项目由该领域的领导者领导，一个行政核心提供监督和管理，一个高度创新的RNAi核心提供关键试剂和基因工程小鼠模型。避免重复工作，智力和物质协同，并以真正的临床需求为导向是其特点